Ron W. Lennox

CHL Healthcare Partners LLC (CHL Medical Partners) is a venture capital firm co-founded in 1997 by Jeff Collinson, Tim Howe and Ron Lennox. The firm is headquartered in Fairfield, Connecticut.

GeneOhm Sciences, Inc. develops molecular diagnostic products. It offers methicillin-resistant staphylococcus aureus (MRSA) Assay an in vitro diagnostic test for the direct detection of MRSA from a nasal specimen. The company was founded on 2001 and is headquartered in Franklin Lakes, NJ.

POINT Biomedical Corp. develops biomedical-imaging products. It manufactures products for diagnostic, molecular imaging, and drug delivery applications based on biSphere technology. The company was founded in 1996 and is headquartered in San Carlos, CA.

PrimeraDx, Inc. develops and commercializes molecular diagnostics systems. It offers ICEPlex System, an open platform that allows clinical researchers to design their assays for the development of multiplexed, multimodal, and quantitative in vitro diagnostic to simultaneously interrogate dozens of biomarkers in the same reaction. The company's ICEPlex System also enables to design complex multi-modal assays that test for disparate target types, such as SNPs, expression biomarkers, miRNAs, and fusion genes, as well as addresses research challenges in oncology, infectious diseases, translational medicine research, and pharma quality control. It also focuses on developing oncology products that are intended to support cancer research, diagnostics, and therapeutics; and companion diagnostics solutions that help pharmaceutical companies to design, develop, and validate custom CDx tests. The company was founded by Vladimir I. Slepnev in 2004 and is headquartered in Mansfield, MA.

BioRelix, Inc. engages in the development of antibiotics. The company was founded by Henry Ford, Howard Hughes, Steven Delco, Ronald R. Breaker and Kennth F. Blount in 2005 and is headquartered in New Haven, CT.

Thetis Pharmaceuticals LLC is a biopharmaceutical company. It improves the lives of patients suffering from gastrointestinal diseases. The company’s proprietary HEALER™ technology platform enables the pharmaceutical development of bioactive lipids, including resolving and other fatty acids, that actively regulate inflammation resolution and tissue repair. Its technologies are pro-resolving lipids and intellectual property. The company was founded by Frank C. Sciavolino, Banavara L. Mylari and Gary Mathias in 2011 and is headquartered in Southport, CT.